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Abstract: 
 
High consumption of fructose-sweetened beverages has been linked to a high 
prevalence of chronic metabolic diseases. We have previously shown that a short 
course of fructose supplementation as a liquid solution induces glucose intolerance 
in female rats. In the present work, we characterized the fructose-driven changes in 
the liver and the molecular pathways involved. To this end, female rats were 
supplemented or not with liquid fructose (10% w/v) for 7 or 14 days. Glucose and 
pyruvate tolerance tests were performed, and the expression of genes related to 
insulin signaling, gluconeogenesis and nutrient sensing pathways was evaluated.   
Fructose-supplemented rats showed increased plasma glucose excursions in 
glucose and pyruvate tolerance tests and reduced hepatic expression of several 
genes related to insulin signaling, including insulin receptor substrate-2 (IRS-2). 
However, the expression of key gluconeogenic enzymes, glucose-6-phosphatase 
and phosphoenolpyruvate carboxykinase, was reduced. These effects were caused 
by an inactivation of hepatic forkhead box O1 (FoxO1) due to an increase in its 
acetylation state driven by a reduced expression and activity of sirtuin 1 (SIRT1). 
Further contributing to FoxO1 inactivation, fructose consumption elevated liver 
expression of the spliced form of X-box-binding-protein-1, as a consequence of an 
increase in the activity of the mammalian target of rapamycin 1 and protein 38-
mitogen activated protein kinase (p38-MAPK). Liquid fructose affects both insulin 
signaling (IRS-2 and FoxO1) and nutrient sensing pathways (p38-MAPK, mTOR and 
SIRT1) thus disrupting hepatic insulin signaling without increasing the expression of 
key gluconeogenic enzymes. 
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Introduction 
 
During the last decade, there has been an increasing number of published 
epidemiological and interventional studies on human populations linking the high 
consumption of sugar-sweetened beverages, enriched in simple sugars such as 
fructose and glucose, to the high prevalence of chronic metabolic and related 
cardiovascular diseases [1-4]. These diseases include dyslipidemia [5,6], gout [7], 
hypertension [8,9], obesity [10,11], insulin resistance [12] and type 2 diabetes 
mellitus [10, 13-15]. High energy intake, lack of adequate energy compensation 
through a proportional decrease in the amount of energy ingested as solid foods, 
and the special metabolism of fructose, have been reported to contribute to this 
possible causal association [2,3]. 
 
Among the experimental animal models used, fructose-fed rats can reproduce 
metabolic alterations induced by fructose consumption in humans. Rats, like 
humans, cannot transform ingested fructose into glucose [16]. Moreover, in both rats 
and humans, continuous fructose ingestion induces the expression of fructokinase, 
an enzyme that drives fructose into liver metabolic pathways [17-19]. The changes 
associated with the human metabolic syndrome can be  reproduced in rats by 
providing them fructose as a 10% w/v solution [20-22]. This mimics the level of 
dietary consumption of sweetened beverages (as a percentage of the daily caloric 
intake about 30%) that leads to clear metabolic disturbances in humans [23,24]. 
Using this model, we recently discovered a gender difference in the response to 
fructose-consumption, with clear signs of glucose intolerance after a short 14-day 
course of fructose supplementation in female, but not male, rats [17]. We also found 
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that fructose-fed female rats displayed a significantly reduced expression of liver 
insulin-related substrate-2 (IRS-2) [17], one of the key insulin-signaling proteins in 
the liver [25].  
 
We therefore pursued the search for the molecular mechanism underlying the 
glucose intolerance observed after fructose supplementation in female rats. In the 
present work, we show that fructose induces a set of complex molecular alterations 
in the liver expression of nutrient sensing factors which reduces the expression of 
both liver IRS-2 and gluconeogenic enzymes in fructose-supplemented female rats. 
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Methods 
 
Animals and experimental design 
 
Female Sprague-Dawley rats purchased from Charles River (Barcelona, 
Spain) were maintained with water and food ad libitum at constant humidity and 
temperature with a light/dark cycle of 12 hours.  The animals were randomly 
separated into a control and a fructose-supplemented group (8 and 12 rats per 
group, respectively). Fructose was supplied as a 10 % (weight/volume) solution in 
drinking water for 7 and 14 days. Control animals received no supplementary sugar. 
At the end of this period, animals were killed by decapitation under isoflurane 
anesthesia at 10 a.m.  Food and fructose solution were removed at 8 a.m. To reduce 
the variability in plasma estrogen concentrations, female rats were killed during the 
diestrus period.  
 
Subgroups of female rats were randomly separated into control and fructose-
supplemented groups, as described above, for glucose and pyruvate tolerance tests. 
 
All procedures were conducted in accordance with the guidelines established 
by the University of Barcelona's Bioethics Committee, as stated in the Autonomous 
Government of Catalonia’s Law 5/1995 (21st July). 
 
Sample preparations 
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Blood and liver tissue samples were collected and stored as described 
previously [21]. Total and nuclear extracts were isolated using the Helenius method 
[26]. Protein concentrations were determined by the Bradford method [27].  
 
Lipids, glucose, insulin, adiponectin and leptin analysis  
 
Plasma triglyceride, glucose, insulin, leptin, and adiponectin concentration, 
were measured as described previously [21].  
 
Glucose Tolerance test  
 
After a two hour fast, the rats were anesthetized, and following the collection 
of an unchallenged sample (time 0), a glucose solution of 2 g/kg body weight was 
administered into the peritoneal cavity. During the test, blood was collected from the 
saphenous vein at 15, 30, 60, 90, and 120 min after glucose administration. Glucose 
measurements were performed using a hand-held glucometer. Plasma insulin levels 
were measured at baseline, 15, 60, and 120 min post-glucose administration using a 
rat insulin ELISA kit (Millipore, Billerica, MA). 
 
Pyruvate tolerance test 
 
Rats were injected with sodium pyruvate (2 g/kg i.p.). Plasma glucose levels 
werre determined at 0, 15, 30, 60, 90, 120, and 150 minutes after injection with a 
hand-held glucometer as described above. 
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Cell culture 
 
 Rat hepatoma FaO cells were obtained from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK). The cells were cultured in low glucose DMEM 
(Gibco, Life Technologies, Madrid, Spain) supplemented with 10% fetal bovine 
serum (FBS Gold, PAA, Pistcataway, NJ) and antibiotics (100 U/mL penicillin and 
100 µg/mL streptomycin, Gibco, Life Technologies, Madrid, Spain). When cells 
reached 80% confluence, the proportion of serum was reduced to 1% and the cells 
were incubated in the absence or presence of fructose (Sigma-Aldrich, St. Louis, 
MO) at a concentration of 25 mM for 24 hours. 
RNA preparation and analysis 
 
Total RNA was isolated using the TrizolR reagent (Invitrogen, Life 
Technologies, Madrid, Spain). The levels of specific mRNAs were assessed by real-
time reverse transcription–polymerase chain reaction (RT–PCR) using Sybergreen 
PCR Master Mix, specific primers and the Applied Biosystems One- 
Step Plus sequence detection system (Applied Biosystems, Foster City,CA). For 
G6Pc, PEPCK and XBP-1, we used conventional RT-PCR as described previously 
[34]. Adenosyl phosphoribosyl transferase (APRT) or 18S was used as an internal 
control. The primer sequences, resulting PCR products and number of cycles are 
listed in Supporting Table 1. 
 
 Western-blot analysis 
 
 9 
 Ten to thirty micrograms of different protein fractions from the rat livers were 
subjected to SDS-polyacrylamide gel electrophoresis. Proteins were then transferred 
to Immobilon polyvinylidene difluoride transfer membranes (Millipore, Billerica, MA), 
blocked for 1 h at room temperature with 5% non-fat milk solution in 0.1% Tween-20-
Tris-buffered saline (TBS), and incubated as described previously [21].  Detection 
was performed with the ECL chemiluminescence kit for HRP (Amersham GE 
Healthcare Europe GmbH, Barcelona, Spain). To confirm the uniformity of protein 
loading, the blots were incubated with the -actin or -tubulin antibody (Sigma-
Aldrich, St. Louis, MO) as a control. The size of the detected proteins was estimated 
using protein molecular-mass standards (Invitrogen, Life Technologies, Madrid, 
Spain).  Antibodies were obtained from Santa Cruz Technologies (Santa Cruz, CA), 
except those for phospho- and total protein kinase B or Akt, phospho- and total p38-
MAPK and PP2Ac, which were obtained from Cell Signaling (Danvers, MA), and 
phospho- and total mTOR, purchased from Millipore (Billerica, MA). 
Co-immunoprecipitation 
Two hundreds micrograms of protein extracts were precleared in preclearing 
matrix F (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h at 4 ºC, and the 
resulting supernatant was immunoprecipitated for 4 h at 4 °C with 4 μg of anti-acetyl-
lysine (Cell Signalling, Denvers, MA) in a final volume of 0.5 mL made up with buffer 
containing 10 mM phosphate-buffered saline (PBS) and 2% bovine serum albumin 
(BSA).  Immunocomplexes were captured by incubating the samples with protein A-
agarose suspension (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4 °C 
on a rocker platform. Agarose beads were collected by centrifugation and washed 
three times with PBS-containing protease inhibitors. After microcentrifugation, the 
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pellet was re-suspended with 60 μL of SDS-PAGE sample buffer and boiled for 5 
min at 100 °C. The supernatant was subjected to electrophoresis on 10% SDS-
PAGE and immunoblotted with an antibody against FoxO1 (Santa Cruz 
Biotechnology, Santa Cruz, CA). 
 PCR-arrays 
 
 Total RNA was isolated from control and fructose-fed rats as described above, 
and then purified using RNeasy kit columns (Qiagen Iberia, Madrid, Spain). Single 
stranded cDNA and PCR arrays were performed using the Rat Insulin Signaling 
Pathway RT2 Profiler PCR Array (PARN-030E) from SABiosciences (Quiagen Iberia, 
Madrid, Spain), following the manufacturer’s guidelines. Array data processing and 
analysis were performed using a Web portal from SABiosciences. 
 
Statistics 
 
The results are expressed as the mean of n values  standard deviation.  
Plasma samples were assayed in duplicate. Significant differences were established 
by the unpaired t-test, one-way ANOVA test (with a posteriori analysis) for cell-
culture experiments, or the two-way ANOVA test (with a posteriori analysis) for 
plasma analytes, using the computer program GraphPad InStat (GraphPad Software 
V2.03). When the number of animals was too small or the variance was not 
homogeneous, a non-parametric Mann-Whitney test was performed for comparing 
two groups. * P < 0.05, ** P < 0.01; # P < 0.001 14-day control vs 7-day control, in 
Tables and Figures.  
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Results  
 
  A 14-day course of fructose ingestion in liquid form is sufficient to 
induce glucose intolerance in female Sprague-Dawley rats. Fructose 
administration as a 10 % weight/volume liquid solution to female Sprague-Dawley 
rats increased energy intake by 26% and 29% after 7- and 14 days of 
supplementation, respectively, compared to the amount of energy consumed by 
control animals, despite fructose-supplemented rats reducing the ingestion of their 
solid diet by 22%. In agreement with our previous results [17], fructose consumption 
by female rats did not modify body weight, but increased plasma glucose and insulin 
concentrations only after the 14-day course of fructose-supplementation, thus 
significantly reducing the insulin sensitivity index (ISI) in these animals (Table 1). 
Furthermore, only the rats supplemented for 14 days displayed changes in their 
glucose tolerance test (GTT), with a significant 30% increase in the area under the 
curve (AUC) value for plasma glucose concentration (Table 1). Again, confirming our 
previous results [17], livers from 14-day fructose-supplemented rats showed a 
marked reduction in the expression of IRS-2 protein (Figure 1a), the main transducer 
of insulin signaling in liver tissue [28], and  a significant increase (1.28-fold) in the 
amount of the active form of protein phosphatase 2 A (PP2Ac), a marker of 
increased fructose metabolism (Figure 1b). Moreover, in FaO rat hepatoma cells, 
incubation with 25 mM fructose for 24 hours blunted the increase in the IRS-2 protein 
levels induced by a short course (10 min) of insulin treatment (Supporting Figure 1a). 
Thus, to confirm fructose-mediated impairment of insulin signaling, we determined 
the expression of V-akt murine thymoma viral oncogene homolog-2 (Akt-2), one of 
the main transducers of insulin signaling downstream of IRS-2, in vivo and in FaO 
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cells. Despite the mild hyperinsulinemia present in Sprague-Dawley rats after 14-
days of fructose-supplementation (see Table 1), neither the active, phosphorylated 
form of Akt, nor total Akt was not significantly affected in the livers of these rats 
(Figure 1c and d). Moreover, although insulin could significantly increase the amount 
of phosphorylated Akt in FaO cells (1.66-fold), this increase was partially blocked by 
incubation with 25 mM fructose for 24 hours (Supporting Figure 1b). At the same 
time, fructose markedly elevated the amount of total Akt in insulin-treated FaO cells, 
further decreasing the ratio of phosphorylated-Akt to total Akt with respect to insulin-
treated cells (1.94 vs 0.88, 0.45-fold).  Due to the decreased liver-insulin signaling in 
fructose-supplemented rats, the bolus-administration of a direct gluconeogenic 
precursor such as pyruvate, significantly increased (1.33-fold) the liver output of 
glucose in rats after 14-days of fructose (Figure 1e and 1f). 
 
  Fructose disrupts insulin signaling in the liver. To gain an overview of the 
effect of fructose on the expression of genes related to insulin signaling, we applied 
the Rat Insulin Signaling Pathway RT2 Profiler PCR Array (see Experimental 
Procedures) to liver samples obtained from female rats supplemented with fructose 
for 7- and 14-days. As shown in Table 2, two clear patterns of changes in gene 
expression were detected: (1) an increase in the expression of genes related to lipid 
synthesis, such as acc (acetyl-CoA Carboxylase), fas (fatty acid synthase) and l-pk 
(liver-pyruvate kinase) at the two time-points studied; and (2) a decrease in the 
expression of genes related to insulin and insulin-growth factor signaling, such as irs-
2, cap1 (adenylate cyclase associated protein 1), and dok1 and 3 (docking protein 1 
and 3), confirming a deficit in the expression of key genes involved in insulin signal 
transduction. Surprisingly, the expression of two key gluconeogenic genes, g6pc 
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(glucose-6-phosphatase) and pck (phosphoenolpyruvate carboxykinase or PEPCK), 
was hardly affected in the livers of 14-day fructose-supplemented rats. Theoretically, 
disrupted insulin-signalling should trigger an increase in liver gluconeogenesis, as 
shown by the results obtained in the pyruvate-chalenge test (see Figure 1e and 1f), 
mainly through the increased expression and activity of G6Pc and PEPCK [29]. In 
fact, when we reassessed the mRNA levels fof G6Pc and PEPCK using gene-
specific conditions, we detected significant reductions in the expression of G6Pc and 
PEPCK in the livers of 14-day fructose-supplemented rats (0.74- and 0.36-fold for 
G6Pc and PEPCK, respectively) (Supporting Figure 2a and b). The liver protein 
levels of both enzymes were also decreased (0.76- and 0.58-fold for G6Pc and 
PEPCK, respectively), although not significantly (Supporting Figure 2c and d). 
 
  To explain the increased hepatic glucose output despite a decreased 
expression of key gluconeogenic enzymes, we examined the expression of other 
enzymes controlling the substrate flux from cytosolic pyruvate to glucose formation 
(Figure 2). We found an increased expression of malate dehydrogenase (1.39-fold) 
and malic enzyme (2.90-fold) in the livers of 14-day fructose-supplemented rats 
(Figure 2e and 2f). In the case of very high concentrations of pyruvate, such as in the 
pyruvate tolerance test, the combined increase in the activities of malate 
dehydrogenase and malic enzyme could generate an amount of oxalacetate 
(substrate of PEPCK) sufficient to significantly increase the liver output of glucose in 
14-day fructose-supplemented rats, despite the reduced expression of both G6Pc 
and PEPCK. Thus, we decided to explore the possible molecular mechanisms 
involved in the fructose-mediated reduction of liver gluconeogenic enzymes 
expression. 
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  Fructose selectively modifies key liver transcription factors involved in 
the expression of the g6pc and pck genes. Peroxisome proliferator coactivator-1 
alpha (PGC-1) and FoxO1 transcription factors control the liver expression of the 
g6pc and pck genes [30,31]. Very recently, the spliced form of X-box-binding-protein-
1 (XBP-1s) was directly implicated in the regulation of liver glucose homeostasis 
through an interaction with FoxO1 [32]. Hence, we were interested in assessing the 
expression of these transcription factors in liver samples from 7- and 14-day 
fructose-supplemented rats. Although the expression of PGC-1 was not modified 
(data not shown), fructose supplementation significantly increased XBP-1s 
expression, especially after 14-days (Figure 3). The effect of fructose on FoxO1 
expression was very complex. Activation of the insulin signaling cascade, through 
the PIK3-IRS-2-Akt pathway, phophorylates FoxO1, which then exits the nucleus 
and translocates to the cytosol, leading to the suppression of gluconeogenic gene 
expression [31]. In liver samples from 14-day fructose-supplemented rats, the 
amount of the inactive, phosphorylated form of FoxO1 was increased (1.78-fold), 
while the total amount of FoxO1 protein was decreased (0.87-fold), further increasing 
the ratio of inactive phospho-FoxO1 to total FoxO1 (2.10-fold) (Figure 4a, 4b and 
4c). Despite this, the amount of FoxO1 protein present in liver nuclear extracts rose 
by 2.08-fold in the livers of 14-day fructose-supplemented rats (Figure 4d). Thus, 
although the liver insulin- IRS-2-Akt signaling pathway was suppressed by fructose 
(see Figure 1), FoxO1 was phosphorylated (and inactivated), but remained in the 
nuclear compartment.  
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  Fructose significantly changes the activity and expression of key 
nutrient-sensing molecules in the liver. To decipher the complex changes 
induced by fructose in insulin signaling, we focused our attention on three key 
molecular transducers involved in nutrient sensing in liver cells: mTOR [33], the 
stress kinase p-38 MAPK [34], and SIRT1 [33]. As shown in Figure 5, fructose 
enhanced the phosphorylated, active form of mTOR (Figure 5a) (1.7-fold) and p-38 
MAPK (Figure 5b) (2.7-fold) only in the livers of 14-day fructose-supplemented rats. 
On the contrary, SIRT1 protein levels were markedly reduced (Figure 6a) (0.51-fold), 
again only in the livers of 14-day fructose-supplemented rats. To confirm that both 
SIRT1 expression and activity were decreased by fructose supplementation, we 
assessed the presence of one of its substrates, acetylated-FoxO1 [35]. Indeed, the 
amount of acetylated-FoxO1 was markedly increased in liver samples from 14-day 
fructose-supplemented rats (Figure 6b), consistent with the decreased SIRT1 activity 
in these samples. When we assessed the effect of fructose on the expression of 
mTOR, p-38 MAPK and SIRT1 in FaO cells, only the phosphorylated, active form of 
p-38 MAPK was increased (1.23-fold, Supporting Figure 3b).   
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Discussion    
   
We previously demonstrated that a short course (14 days) of fructose 
supplementation as a liquid solution was sufficient to induce glucose intolerance only 
in female, but not male, rats [17]. In the present work, we detected a clear rise in the 
liver glucose output after a bolus administration of a direct gluconeogenic precursor, 
such a pyruvate, to 14-day fructose-supplemented rats. Higher than usual plasma 
concentrations of glucose in control animals were due to the fact that rats were 
fasted only two hours before sacrifice (see Animals and experimental design). 
However, we were surprised to note a significant reduction in the expression of two 
key gluconeogenic enzymes, PEPCK and G6Pc, despite a clear impairment in 
insulin signaling in the livers of these rats. Thus, we searched for the molecular cues 
that could explain this situation. Our main findings indicate that through a complex 
chain of molecular changes affecting both insulin signalling (IRS-2 and FoxO1) and 
nutrient sensing pathways (p38-MAPK, mTOR and SIRT1), fructose metabolism in 
the liver disrupt insulin signalling without affecting, or even decreasing, the 
expression of key gluconeogenic enzymes. These results suggest that the path from 
fructose consumption to the production of insulin resistance is not as straightforward 
as previously thought. Moreover, these changes seem to be specifically related to 
fructose consumption, and not to general changes in the amount of solid food 
ingested or total energy intake. Although solid food consumption was reduced by 
22% by fructose ingestion, the amount of macro- and micronutrients ingested daily 
by the fructose-supplemented animals was equally or above the estimated nutrient 
requirements for maintenance and growth of rats (see Supplemental Table 2). 
Furthermore, we have shown previously that rats supplemented with a 10 % 
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(weight/volume) liquid solution of glucose, despite ingesting the same amount of 
energy as rats supplemented with a 10% liquid solution of fructose, they did not  
show similar changes in main metabolic parameters, such as plasma and liver 
triglyceride, PPARα expression and β-oxidation activity [21].  
 
p38-MAPK is a stress-related kinase [34] whose activity can be increased by 
the metabolic burden imposed by fructose metabolism in hepatocytes through two 
mechanisms: increased activity of protein phosphatase 2A [36] and the presence of 
bacterial toxins in blood, as a result of fructose-mediated changes in the intestinal 
barrier permeability [37,38]. Indeed, we could detect a clear increase in the 
phosphorylated, activated form of p38-MAPK only in the liver samples of 14-day 
fructose-supplemented rats, which coincided with an increased expression of the 
catalytic form of PP2A. 
   
It has been described that increased p38-MAPK activity, by phosphorylating 
the tuberous sclerosis 2 gene product or tuberin, could release its inhibitory activity 
on mTORC1 (mammalian Target of Rapamicyn Complex 1) [39]. The mTOR 
signaling pathway transduces information from different signals, such as growth 
factors, amino acids, and energy overload in the cell [40] . In accordance with an 
increased energy load and p38-MAPK activity, liver samples from 14-day fructose-
supplemented rats showed a clear increase in the phosphorylated, activated form of 
mTOR. As it has been shown that mTOR activation causes IRS-2 degradation [41], 
the increase in mTOR activity could be the final factor resulting in the decreased liver 
expression of IRS-2 induced by fructose-consumption. Furthermore, since p38-
MAPK can phosphorylate FoxO1 [42], the increased p38-MAPK activity could 
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explain the elevated amount of phosphorylated, inactive FoxO1 in the livers of 14-
day supplemented rats, despite the lack of insulin-mediated Akt activation. 
 
FoxO1 presented two other anomalies in the livers of 14-day supplemented 
rats, namely a reduction in its total cellular amount and a nuclear localization, despite 
being hyperphosphorylated. A recent report demonstrated that XBP-1, an 
endoplasmic reticulum stress transcription factor, plays an essential role in 
maintaining plasma glucose concentration and glucose tolerance [32], interacting 
with FoxO1 and directing it toward proteasome degradation, as well as improving the 
control of plasma glucose concentrations even without enhancing insulin signalling. 
Moreover, it has been described that mTORC1 activity increases the splicing of 
XBP-1 [43], while p38-MAPK phosphorylates the splice-derived protein, facilitating its 
nuclear localization and activity [44]. Indeed, in accordance with the increased 
activity of mTOR and p38-MAPK, there was a marked increase in the spliced form of 
XBP-1 mRNA and nuclear protein in the livers of 14-day fructose-supplemented rats, 
thus giving a plausible explanation for the reduced amount of total FoxO1 protein in 
these samples.  
  
FoxO1 activity can be regulated not only by phosphorylation, but also by 
acetylation. Liu et al. described that acetylated-FoxO1, although displaying reduced 
transcriptional activity, is retained mainly in the nucleus [45]. The NAD+-dependent 
deacetylase SIRT1 controls metabolic processes in response to low nutrient 
availability [46], mediating the direct deacetylation of several transcription factors 
including FoxO1 [35]. Situations of energy overload, such as a high-fat diet, reduces 
SIRT1 expression and/or activity [47]. Consistently with the increased amount of 
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energy consumed by fructose-supplemented rats, SIRT1 expression was 
significantly reduced in the livers of 14-day fructose-supplemented rats. As a 
consequence of the reduced deacetylation activity, the amount of acetylated-FoxO1 
was increased in the same samples, thus explaining the increased nuclear 
localization of FoxO1 in the livers of fructose supplemented rats. 
 
The combined increases in the liver activities of malate dehydrogenase and 
malic enzyme could explain the increased liver output of glucose in 14-day fructose-
supplemented rats submitted to the pyruvate tolerance test, despite the reduced 
expression of both G6Pc and PEPCK. Nevertheless, this situation indicates that in 
these animals, the altered ISI is not due to an increased output of liver glucose. New 
experiments should be performed in order to ascertain the existence of a state of 
skeletal muscle insulin resistance in 14-day fructose-supplemented rats. Decreased 
muscular consumption of glucose could explain the observed increase in the AUC 
for the glucose tolerance test in 14-day fructose-supplemented rats. 
 
Further studies using chronic fructose supplementation should be performed 
in order to ascertain whether this situation persists in time or evolves to a typical liver 
insulin resistance with increased gluconeogenesis. This is an important issue, given 
the epidemiological evidence relating consumption of fructose sweetened beverages 
over time and insulin resistance and type 2 diabetes mellitus in human populations.  
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 Figure Legends 
 
Figure 1: Expression of proteins involved in insulin signaling in the livers of fructose-
supplemented female rats. Western-blot of IRS-2 (a), PP2Ac (b), and phospho- (c) 
and total Akt (d) proteins in the liver samples from control and fructose-
supplemented female rats. For each protein, representative bands corresponding to 
three different rats in each treatment group are shown. Bar plots show the levels of 
each protein, expressed as the mean (a.u., arbitrary units) ± sd of the values 
obtained from 6 animals, in the hepatic samples from control (white bar) and 
fructose-supplemented (black bar) rats. The amount of protein loaded was confirmed 
by the Bradford method, and the uniformity of protein loading in each lane was 
assessed using -actin as the loading control. (e) Plasma glucose concentrations 
after the injection of pyruvate (2 g/kg i.p.). (f) The mean value of the area under the 
curve, expressed as g of glucose/150 min/animal, for control and fructose-
supplemented rats.  
 
Figure 2: Expression of enzymes related to glucose metabolism in the livers of 14-
day fructose-supplemented female rats. The mRNA levels of liver pyruvate 
dehydrogenase kinase 2 (PDK2) (a),  pyruvate dehydrogenase kinase 4 (PDK4) (b), 
ATP citrate lyase (ACLY) (c), malate dehydrogenase (MD) (d), and malic enzyme 
(ME) (e) in the hepatic samples from control (white bar) and fructose-supplemented 
female (black bar) rats are given. Each bar represents the mean ± sd of the values 
obtained from 6 animals. Specific mRNA levels were determined by real-time PCR 
as described in the Experimental Procedures section. 
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Figure 3: X-box-binding-protein-1 (XBP-1) expression in the livers of control and 
fructose-supplemented rats. (a) Autoradiograph of an agarose gel showing bands 
corresponding to unspliced (u) and spliced (s) XBP-1 mRNA in liver samples 
corresponding to four control and four fructose-supplemented rats for each time 
point. Western-blot of the spliced form of XBP-1 (XBP-1s)  (b) in the livers of control 
and fructose-supplemented female rats. A bar plot (c) shows the levels of the 
proteins, expressed as the mean (a.u., arbitrary units) ± sd of the values obtained 
from 6 animals, in the hepatic samples from control (white bar) and fructose-
supplemented (black bar) rats. The amount of protein loaded was confirmed by the 
Bradford method, and the uniformity of protein loading in each lane was assessed 
using -tubulin as loading control. 
 
Figure 4: Forkhead box O1 (FoxO1) protein expression in the livers of control and 
fructose-supplemented rats. Western-blot of phospho-FoxO1 (a), and total FoxO1 
levels in liver whole-homogenates (b) and nuclear extracts (d) from control and 
fructose-supplemented female rats. A bar plot shows the levels of the proteins, 
expressed as the mean (a.u., arbitrary units) ± sd of the values obtained from 6 
animals, in the hepatic samples from control (white bar) and fructose-supplemented 
(black bar) rats. The amount of protein loaded was confirmed by the Bradford 
method, and the uniformity of protein loading in each lane was assessed using of -
actin as loading control. (c) A bar plot showing the ratio of phospho- to total FoxO1, 
expressed as the mean (a.u., arbitrary units) ± sd of the values obtained from 6 
animals, in whole liver homogenates from control (white bar) and fructose-
supplemented (black bar) rats. 
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Figure 5: Activity of nutrient-sensing kinases is increased in the livers of 14-day 
fructose-supplemented rats. Western-blot of phospho- and total  mTOR (a), and 
phospho and total p38-MAPK (b) proteins in the livers of control and fructose-
supplemented female rats. For each protein, representative bands corresponding to 
three different rats in each treatment group are shown. As a measure of the degree 
of kinase activation, bar plots show the ratio of the phospho- to the total contents of 
each kinase, expressed as the mean (a.u., arbitrary units) ± sd of the values 
obtained from 6 animals, in the hepatic samples from control (white bar) and 
fructose-supplemented (black bar) rats. The amount of protein loaded was confirmed 
by the Bradford method, and the uniformity of protein loading in each lane was 
assessed using -actin as loading control.  
 
Figure 6: Sirtuin 1 (SIRT1) expression and activity is decreased in the livers of 14-
day fructose-supplemented rats. Western-blot of SIRT1 protein (a) in the livers of 
control and fructose-supplemented female rats. Representative bands corresponding 
to three different rats in each treatment group are shown. Bar plots show the protein 
level, expressed as the mean (a.u., arbitrary units) ± sd of the values obtained from 6 
animals, in the hepatic samples from control (white bar) and fructose-supplemented 
(black bar) rats. The amount of protein loaded was confirmed by the Bradford 
method, and the uniformity of protein loading in each lane was assessed using -
actin as loading control. As an indirect measure of SIRT1 activity, the amount of the 
acetylated form of FoxO-1 (b) in the liver samples from control and fructose-
supplemented animals was determined by co-immunoprecipitation, as described in 
the Experimental Procedures section. 
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Table 1: Fructose effects on líquid and food ingestions, plasma analytes, 
insulin sensitivity inndex and glucose tolerance test 
 
 7 days 14 days 
 Control Fructose Control Fructose 
AUC ingested líquid 
 (ml/days/2 rats) 
360 ± 8 845 ± 198* 706 ± 91 1995 ± 430* 
AUC consumed diet  
(g/days/2 rats) 
227 ± 2 177 ± 13** 503 ± 12 392 ± 44* 
Body Weight (g) 249 ± 7 257 ± 19 264 ± 26 278 ± 21 
Adiponectin µg/ml 2.7 ± 0.7 3.9 ± 1.5 2.3 ± 0.7 4.0 ± 0.7* 
Leptin ng/ml 2.0 ± 1.0 3.2 ± 2.3 2,8 ± 2,7 4.7 ± 2.2 
Insulin µg/ml 0.46 ± 0.07 0.65 ± 0.26 0.51 ± 0.12 0.94 ± 0.43* 
Glucose mg/dl 151 ± 7 158 ± 11 190 ± 12
#
 
 
210 ± 16*  
ISI 1.21 ± 0.07 1.09 ± 0.14 1.06 ± 0.14
# 
 
0.76 ± 0.21*  
AUC glucose concentration for 
glucose tolerance test  
(% versus control) 
100±15 100±12 100±23 132±25* 
 
Table 1
Table 2: Change in gene expression after 7 or 14 days of fructose feeding for a 
selection of genes analyzed using real time PCR arrays (Rat Insulin Signaling 
Pathway RT2 Profiler)   
 
Description Symbol 
7 days 14 days 
Fold change P value Fold change P value 
CAP adenylate cyclase-
associated protein-1 
Cap-1 0.883 0.340 0.822 0.029 
Docking protein-1 Dok1 0.933 0.479 0.537 0.052 
Docking protein-3 Dok3 1.165 0.602 0.485 0.044 
GRB2-associated binding 
protein1 
Gab1 0.918 0.624 0.737 0.043 
Insulin-like growth factor1 
receptor 
Igf1r 1.009 0.896 0.551 0.009 
Insulin receptor substrate 1 IRS-1 1.662 0.024 0.640 0.063 
Insulin receptor substrate 2 IRS-2 1.197 0.451 0.545 0.013 
Mitogen activated protein 
kinase 1 
Mapk1 1.012 0.961 0.770 0.032 
Protein kinase C, zeta PrKcz 1.721 0.004 0.349 0.059 
Solute carrier family 27 (fatty 
acid transportar) membre 4 
Slc27a4 0.783 0.189 0.597 0.025 
Son of sevenless homolog 1 Sos1 1.009 0.377 0.781 0.033 
Phosphoenolpyruvate 
carboxykinase 
PEPCK 1.197 0.403 1.313 0.018 
Glucose-6-phosphatase G6Pc 1.598 0.317 0.412 0.19 
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